Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|January 1, 2011||10/6/2014||MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children||Healthy;Cystic Fibrosis (CF);Asthma;Bronchopulmonary Dysplasia (BPD)||Drug: Hyperpolarized Helium-3 MRI of the chest||University of Virginia||Xemed LLC||Completed||4 Months||65 Years||All||77||N/A||United States|
|October 2010||9/7/2010||Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation||A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40% Predicted||Cystic Fibrosis||Drug: VX-770;Drug: Placebo||Vertex Pharmaceuticals Incorporated||Cystic Fibrosis Foundation Therapeutics||Completed||12 Years||N/A||All||13||Phase 2||United States|
|November 2008||16/2/2009||Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders||Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders||COPD;Cystic Fibrosis;Asthma;Healthy||Drug: Hyperpolarized Helium-3||University of Massachusetts, Worcester||NULL||Terminated||5 Years||N/A||All||14||N/A||United States|
|27/03/2017||Study of the Effect of VX-770 on Hyperpolarized Helium-3 MagneticResonance Imaging in Subjects With Cystic Fibrosis and the G551DMutation||A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effectof VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging inSubjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40%Predicted||cystic fibrosis |
MedDRA version: 19.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|Trade Name: Kalydeco|
Product Name: ivacaftor
Product Code: VX-770
INN or Proposed INN: IVACAFTOR
|Vertex Pharmaceuticals Incorporated||NULL||NA||Female: yes|
|17||Phase 2||United States|